Want to see SNOA full AI Analyst Report?
SNOA Stock Chart & Stats
$1.38
<$0.01(0.88%)
At close: 4:00 PM EDT
$1.38
<$0.01(0.88%)
Day’s Range― - ―
52-Week Range$0.85 - $4.10
Previous Close$1.2
Volume25.25K
Average Volume (3M)45.59K
Market Cap
$5.51M
Enterprise Value$131.58K
Total Cash (Recent Filing)$5.34M
Total Debt (Recent Filing)$739.00K
Price to Earnings (P/E)―
Beta2.04
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.22
Shares Outstanding4,788,425
10 Day Avg. Volume46,430
30 Day Avg. Volume45,588
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.16
Price to Sales (P/S)0.18
P/FCF Ratio-0.87
Enterprise Value/Market Cap0.02
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda-0.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.56
Revenue Forecast (FY)$23.91M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginRevenue growth combined with a relatively stable gross margin indicates continued demand for Sonoma’s products and reasonably consistent product-level economics. If maintained, this combination can support operating leverage and improve the company’s ability to absorb fixed costs over the next several quarters.
Manageable LeverageRelatively low debt compared with equity reduces balance-sheet pressure and limits the immediate burden of interest and refinancing obligations. The stated asset and equity base provides some capital cushion, giving Sonoma greater flexibility while it works toward sustainable profitability.
Narrowing LossesAlthough Sonoma remains unprofitable, the multi-year narrowing of losses suggests progress toward a more sustainable cost structure. Continued improvement could allow revenue growth to translate more effectively into earnings, strengthening the company’s financial profile over the two-to-six-month outlook.
Bears Say
Persistent Operating LossesNegative operating and net margins show that Sonoma’s current revenue base does not yet cover its operating cost structure. Persistent losses weaken internal funding capacity and may require continued financial discipline before growth can produce durable shareholder returns.
Negative And Worsening Cash FlowThe company is consuming cash rather than self-funding, and the recent deterioration in free cash flow indicates that cash pressure is not yet resolved. Sustained outflows can constrain investment in commercialization and increase reliance on external financing or other capital sources.
Deeply Negative Return On EquityA deeply negative return on equity indicates that the capital invested in Sonoma is currently generating losses rather than productive returns. If this persists, retained losses can erode the equity cushion and reduce the company’s ability to compound value without a material earnings recovery.
Sonoma Pharmaceuticals News
SNOA FAQ
What was Sonoma Pharmaceuticals’s price range in the past 12 months?
Sonoma Pharmaceuticals lowest stock price was $0.85 and its highest was $4.10 in the past 12 months.
What is Sonoma Pharmaceuticals’s market cap?
Sonoma Pharmaceuticals’s market cap is $5.51M.
When is Sonoma Pharmaceuticals’s upcoming earnings report date?
Sonoma Pharmaceuticals’s upcoming earnings report date is Nov 16, 2026 which is in 25 days.
How were Sonoma Pharmaceuticals’s earnings last quarter?
Sonoma Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported $0.015 earnings per share for the quarter.
Is Sonoma Pharmaceuticals overvalued?
According to Wall Street analysts Sonoma Pharmaceuticals’s price is currently Overvalued.
Does Sonoma Pharmaceuticals pay dividends?
Sonoma Pharmaceuticals does not currently pay dividends.
What is Sonoma Pharmaceuticals’s EPS estimate?
Sonoma Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sonoma Pharmaceuticals have?
Sonoma Pharmaceuticals has 4,788,425 shares outstanding.
What happened to Sonoma Pharmaceuticals’s price movement after its last earnings report?
Sonoma Pharmaceuticals reported an EPS of $0.015 in its last earnings report. Following the earnings report the stock price went up 10.619%.
Which hedge fund is a major shareholder of Sonoma Pharmaceuticals?
Currently, no hedge funds are holding shares in SNOA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygiene, oral health, and various dermatological conditions. The company's market reach extends across the United States, Latin America, Europe, and other international territories. Its comprehensive product line features: Epicyn: an antimicrobial cleanser for facial use. Levicyn: a prescription HOCl-based treatment formulated to ease the burning, itching, and pain associated with numerous dermatological issues. Celacyn gel: a topical HOCl-based prescription product engineered to facilitate efficient healing and management of both new and old scars. SebuDerm: designed to soothe the burning, itching, redness, scaling, and discomfort linked to seborrhea and seborrheic dermatitis. Acuicyn: an HOCl-based solution for alleviating ocular itch and inflammation, while also maintaining cleanliness around the eyes. Microcyn: a topical HOCl product family aimed at accelerating wound healing by combating a wide spectrum of pathogens, including antibiotic-resistant strains that can impede natural recovery. MicrocynAH: an HOCl-based solution specifically for animals, providing relief for common conditions like hot spots, scratches, skin rashes, post-surgical sites, and irritated skin to support healing. Microdacyn60: an oral care solution for treating infections of the mouth and throat. MucoClyns: suitable for emergency use and safe for application on mucous membranes, cuts, abrasions, burns, and other body surfaces. Endocyn: a series of solutions for root canal irrigation. Pediacyn: a hydrogel designed for atopic dermatitis. Ocucyn: a cleanser for eyelids and eyelashes. Gramaderm: for the topical treatment of mild to moderate acne. Nanocyn: a hospital-grade disinfectant. Sinudox: for nasal irrigation purposes. Originally incorporated in 1999 as Oculus Innovative Sciences, Inc., the company officially rebranded to Sonoma Pharmaceuticals, Inc. in December 2016. Its headquarters are located in Woodstock, Georgia.
Technical Analysis
Perrigo Company
―
Organogenesis Holdings
―
Amneal Pharmaceuticals
―
Aquestive Therapeutics
―
Journey Medical Corp
―
Ownership Overview
7.38%
Insiders
0.70% Mutual Funds
0.23% Other Institutional Investors
91.29% Public Companies and
Individual Investors